United States v. Troy

CourtUnited States Air Force Court of Criminal Appeals
DecidedApril 3, 2015
DocketACM S32174
StatusUnpublished

This text of United States v. Troy (United States v. Troy) is published on Counsel Stack Legal Research, covering United States Air Force Court of Criminal Appeals primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States v. Troy, (afcca 2015).

Opinion

UNITED STATES AIR FORCE COURT OF CRIMINAL APPEALS

UNITED STATES

v.

Staff Sergeant DANIEL P. TROY United States Air Force

ACM S32174

3 April 2015

Sentence adjudged 24 May 2013 by SPCM convened at Misawa Air Base, Japan. Military Judge: Natalie D. Richardson.

Approved Sentence: Confinement for 12 months, forfeiture of $1,010.00 pay per month for 12 months, and reduction to E-1.

Appellate Counsel for the Appellant: Major Anthony D. Ortiz and Major Thomas A. Smith.

Appellate Counsel for the United States: Major Daniel J. Breen; Major Mary Ellen Payne; and Gerald R. Bruce, Esquire.

Before

HECKER, SARAGOSA, and TELLER Appellate Military Judges

OPINION OF THE COURT

This opinion is issued as an unpublished opinion and, as such, does not serve as precedent under AFCCA Rule of Practice and Procedure 18.4.

HECKER, Senior Judge:

A special court-martial composed of officer members convicted the appellant, contrary to his pleas, of dereliction of duty; operating a vehicle while impaired; wrongfully using, distributing, and introducing a controlled substance; and soliciting another to use a controlled substance, in violation of Articles 92, 111, 112a, and 134, UCMJ, 10 U.S.C. §§ 892, 911, 912a, 934. The court sentenced him to confinement for 12 months, forfeiture of $1,010.00 pay per month for 12 months, and reduction to E-1. The convening authority approved the sentence as adjudged. On appeal, the appellant contends the military judge erred when she (1) found a presumptive drug test met the requirements for admissibility; (2) admitted a bank statement into evidence; (3) prevented the defense from questioning witnesses about the potential collusion of the appellant’s co-actors; and (4) admitted statements made by the appellant without rights advisement. He also contends (5) the cumulative error of the improperly admitted evidence requires the findings to be set aside and (6) the evidence is factually and legally insufficient to sustain his conviction for operating a vehicle while impaired. Finding no error that materially prejudices a substantial right of the appellant, we affirm the findings and sentence.

Background

The offenses in this case stemmed from the appellant’s alleged involvement with multiple controlled substances, namely dihydrocodeine (found in Bron), oxycodone (found in Percocet), clonazepam (found in Klonopin), lorazepam (found in Ativan), and dextroamphetamine (found in Adderall). Another military member used drugs with the appellant while two others were present when he did so, and all three testified at the appellant’s trial under a grant of immunity.

The appellant’s involvement with controlled substances came to the attention of law enforcement in January 2013 after Senior Airman (SrA) BT self-identified his own abuse of Bron while seeking help for problems he was experiencing. As part of that process, SrA BT stated he had used Bron with the appellant. Bron is an over-the-counter cough medicine sold in Japan that contains dihydrocodeine, an opiate. This led the appellant’s first sergeant to issue a no contact order, prohibiting the appellant from having contact with SrA BT and two other Airmen who were implicated in his involvement with drugs.

SrA BT testified at the appellant’s court-martial that he and the appellant first used drugs together in March 2012, when they crushed and snorted Adderall and Ativan. In June 2012, the two crushed and snorted SrA BT’s prescribed Percocet over a 10-day period.

The two began using Bron in June 2012 after seeing a commercial on the Armed Forces Network warning servicemembers that this cough medicine contains a narcotic and therefore is illegal for them to use, despite being available for purchase in Japanese stores. After doing some research about its effects and detectability through urinalysis testing, the two purchased Bron at a Japanese drugstore and used it for the first time.

Over the next six months, SrA BT saw the appellant use Bron 100 to 150 times. The two took increasing amounts of the drug over time as they developed a tolerance for its effects, and they also switched to a powdered form which had fewer adverse side effects. Eventually they were using it on a daily basis, including at work. To maintain this level of use, the two traveled to local drugstores multiple times per week and brought

2 ACM S32174 the substance onto base in their vehicles. Two other Airmen, Airman First Class (A1C) SR and Airman (Amn) GB testified about their observations of the Bron use and purchases by the appellant and SrA BT. Amn GB also testified that the appellant offered him Bron, which he refused to take.

SrA BT also witnessed the appellant misusing Klonopin he had received through a prescription. Instead of swallowing the prescribed amount, the appellant would chew multiple pills so he would feel the effect faster. The appellant also gave SrA BT two of the pills. The two of the them mixed Klonopin with Bron in order to increase the sensation.

Following a litigated trial, the appellant was convicted of wrongfully using all five controlled substances, distributing clonazepam (Klonopin), introducing dihydrocodeine (Bron) onto Misawa Air Base, and soliciting an Airman to use dihydrocodeine (Bron) by offering it to him.1 The appellant was also convicted of driving a car while impaired by dihydrocodeine (Bron) and clonazepam (Klonopin) and of violating a lawful general order by having contact with the three Airmen after being directed not to do so.

Admissibility of Presumptive Drug Test

At trial, SrA BT testified about one of the times he and the appellant used Bron and Klonopin in combination with the intention of getting “high.” The following morning, the appellant had a seizure while at the Base Exchange and was taken to the base emergency room. While there, he was given a urine drug screening test using a device called the “Alere iCassette.” This test revealed a presumptive positive result for opiates and oxycodone. Prior to trial, the appellant moved to exclude evidence of the results from this testing as too unreliable to meet the evidentiary standard required for scientific evidence to be admissible.

Recognizing the arguments of appellate counsel with regards to Mil. R. Evid. 702 and its interplay with Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, 589 (1993), and United States v. Houser, 36 M.J. 392, 397 (C.M.A. 1993), we need not resolve the admissibility of the drug test if any error in its admission was harmless.

Improper admission of expert testimony is harmless if the error did not have a substantial influence on the findings. United States v. Flesher, 73 M.J. 303, 318 (C.A.A.F. 2014). We determine if an error had a substantial influence by assessing four factors: “(1) the strength of the Government’s case; (2) the strength of the defense’s case; (3) the materiality of the evidence in question; and (4) the quality of the evidence in question.” Id.

1 The appellant was acquitted of distributing lorazepam and dextroamphetamine, obstructing justice by attempting to influence the testimony of the three Airmen, and soliciting Airman First Class SR to use dihydrocodeine.

3 ACM S32174 Although argued substantively by trial counsel, the test results carried limited evidentiary value for a charged timeframe of over eight months, from May 2012 to January 2013. The test was overshadowed by the remaining testimony of multiple witnesses establishing the appellant’s use of controlled substances over 100 times.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Davis v. Alaska
415 U.S. 308 (Supreme Court, 1974)
Daubert v. Merrell Dow Pharmaceuticals, Inc.
509 U.S. 579 (Supreme Court, 1993)
United States v. Pope
69 M.J. 328 (Court of Appeals for the Armed Forces, 2011)
United States v. Freeman
65 M.J. 451 (Court of Appeals for the Armed Forces, 2008)
United States v. Moss
63 M.J. 233 (Court of Appeals for the Armed Forces, 2006)
United States v. Flesher
73 M.J. 303 (Court of Appeals for the Armed Forces, 2014)
United States v. Jones
73 M.J. 357 (Court of Appeals for the Armed Forces, 2014)
United States v. Humpherys
57 M.J. 83 (Court of Appeals for the Armed Forces, 2002)
United States v. Barner
56 M.J. 131 (Court of Appeals for the Armed Forces, 2001)
United States v. Harris
55 M.J. 433 (Court of Appeals for the Armed Forces, 2001)
United States v. Bins
43 M.J. 79 (Court of Appeals for the Armed Forces, 1995)
United States v. Duga
10 M.J. 206 (United States Court of Military Appeals, 1981)
United States v. Turner
25 M.J. 324 (United States Court of Military Appeals, 1987)
United States v. Good
32 M.J. 105 (United States Court of Military Appeals, 1991)
United States v. Bahr
33 M.J. 228 (United States Court of Military Appeals, 1991)
United States v. Brandell
35 M.J. 369 (United States Court of Military Appeals, 1992)
United States v. Banks
36 M.J. 150 (United States Court of Military Appeals, 1992)
United States v. Houser
36 M.J. 392 (United States Court of Military Appeals, 1993)
United States v. Maxwell
38 M.J. 148 (United States Court of Military Appeals, 1993)
United States v. Washington
57 M.J. 394 (Court of Appeals for the Armed Forces, 2002)

Cite This Page — Counsel Stack

Bluebook (online)
United States v. Troy, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-v-troy-afcca-2015.